SCHEMBL4557645

SCHEMBL4557645

O=P(O)(O)OSOP(=O)(O)O

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.44
BLM P54132 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA4 P22748 1/20 0.33
INPPL1 O15357 2/20 0.32
INPP5A Q14642 2/20 0.32
SMPD1 P17405 1/20 0.32
INPP5B P32019 1/20 0.32
CA2 P00918 1/20 0.31
ITPR3 Q14573 3/20 0.30
ITPR2 Q14571 1/20 0.30
ITPR1 Q14643 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18831791 0.81
SCHEMBL3079946 0.81 ALDH1A1 (0.33) FDPSBLMTDP1
SCHEMBL1502473 0.72
SCHEMBL6279518 0.72
SCHEMBL8377664 0.72
SCHEMBL25432405 0.72
Hydrochloric Acid SCHEMBL10613713 0.69
Hydrochloric Acid SCHEMBL11213557 0.69
Pyrophosphoric Acid SCHEMBL8851914 0.61 FDPS (1.00) FDPSBLMTDP1CA4INPPL1
Pyrophosphoric Acid SCHEMBL292348 0.61 FDPS (1.00) FDPSBLMTDP1CA4INPPL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023217708-A1 PHOSPHORUS-31 MRI AGENTS UNIVERSITEIT TWENTE (NL) 2023-11-16 WO claimed
WO-2023217708-A1 PHOSPHORUS-31 MRI AGENTS UNIVERSITEIT TWENTE (NL) 2023-11-16 WO disclosed
WO-2023217708-A1 PHOSPHORUS-31 MRI AGENTS UNIVERSITEIT TWENTE (NL) 2023-11-16 WO disclosed
CN-109890831-A Substituted nucleosides, nucleotide and their analog 詹森生物制药有限公司 2019-06-14 CN disclosed
CN-109843302-A Compounds, compositions and methods for treating diseases 斯必乐维生物科学公司 2019-06-04 CN disclosed
CN-104694628-B Using the activated polymerization nucleic acid reacted by polyphosphoric acid decomposition (APP) 生命技术公司 2017-06-06 CN disclosed
US-8399196-B2 Nucleic acid sequencing methods, kits and reagents GENEFORM TECHNOLOGIES LIMITED (GB) 2013-03-19 US disclosed
EP-1594987-B1 NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS GENEFORM TECHNOLOGIES LTD (GB) 2009-05-27 EP disclosed
US-20070148645-A1 Nucleic acid sequencing methods, kits and reagents GENEFORM TECHNOLOGIES LIMITED (GB) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070148645-A1 Nucleic acid sequencing methods, kits and reagents UNG, DNTT, RNGTT FDPS 964/4885BLM 296/4885TDP1 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.